Nadmed is a Helsinki-based biotech company that has developed a testing method to measure all four NADs and glutathione forms from fresh blood samples. Its assay uses an accurate colorimetric quantification that can be performed on minuscule amounts of blood and is said to deliver the same accuracy as mass spectrometry. The test can be run quickly and efficiently and measures NADs and glutathiones from the same sample. Nadmed currently serves customers in 27 countries, including clinical laboratories (e.g., Synlab), universities (e.g., Newcastle University), research institutions (e.g., NIH), and pharmaceutical companies (e.g., Clene Nanomedicine). The company is led by CEO Jari Närhi and intends to use the funds to expand operations and advance development efforts. Financially, it has secured a €3.5M Series A round alongside a public grant to support its growth.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2024